These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1223 related articles for article (PubMed ID: 24494635)
1. An update on new and emerging therapies for relapsing-remitting multiple sclerosis. Weinstock-Guttman B Am J Manag Care; 2013 Nov; 19(17 Suppl):s343-54. PubMed ID: 24494635 [TBL] [Abstract][Full Text] [Related]
2. Oral disease-modifying therapies for relapsing-remitting multiple sclerosis. Thomas RH; Wakefield RA Am J Health Syst Pharm; 2015 Jan; 72(1):25-38. PubMed ID: 25511835 [TBL] [Abstract][Full Text] [Related]
5. Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Hutchinson M; Fox RJ; Havrdova E; Kurukulasuriya NC; Sarda SP; Agarwal S; Siddiqui MK; Taneja A; Deniz B Curr Med Res Opin; 2014 Apr; 30(4):613-27. PubMed ID: 24195574 [TBL] [Abstract][Full Text] [Related]
6. Balancing the benefits and risks of disease-modifying therapy in patients with multiple sclerosis. Sørensen PS J Neurol Sci; 2011 Dec; 311 Suppl 1():S29-34. PubMed ID: 22206763 [TBL] [Abstract][Full Text] [Related]
13. Real-world propensity score comparison of treatment effectiveness of peginterferon beta-1a vs. subcutaneous interferon beta-1a, glatiramer acetate, and teriflunomide in patients with relapsing-remitting multiple sclerosis. Reder AT; Arndt N; Roman C; Geremakis C; Mendoza JP; Su R; Makin C; Avila RL; Vignos MC Mult Scler Relat Disord; 2021 Jun; 51():102935. PubMed ID: 33882426 [TBL] [Abstract][Full Text] [Related]
14. Ponesimod (Ponvory) for multiple sclerosis. Med Lett Drugs Ther; 2021 Aug; 63(1630):123-125. PubMed ID: 34550110 [No Abstract] [Full Text] [Related]
15. New FDA-Approved Disease-Modifying Therapies for Multiple Sclerosis. English C; Aloi JJ Clin Ther; 2015 Apr; 37(4):691-715. PubMed ID: 25846320 [TBL] [Abstract][Full Text] [Related]
16. Impact of diagnosis and early treatment on the course of multiple sclerosis. Noyes K; Weinstock-Guttman B Am J Manag Care; 2013 Nov; 19(17 Suppl):s321-31. PubMed ID: 24494633 [TBL] [Abstract][Full Text] [Related]
17. New and Emerging Disease-Modifying Therapies for Relapsing-Remitting Multiple Sclerosis: What is New and What is to Come. Nicholas J; Morgan-Followell B; Pitt D; Racke MK; Boster A J Cent Nerv Syst Dis; 2012; 4():81-103. PubMed ID: 23650470 [TBL] [Abstract][Full Text] [Related]
18. New treatments and treatment goals for patients with relapsing-remitting multiple sclerosis. Fox EJ; Rhoades RW Curr Opin Neurol; 2012 Feb; 25 Suppl():S11-9. PubMed ID: 22398660 [TBL] [Abstract][Full Text] [Related]
19. [Update on current care guidelines: multiple sclerosis]. Duodecim; 2013; 129(5):548-9. PubMed ID: 23520898 [TBL] [Abstract][Full Text] [Related]